Nov 18 (Reuters) - Canadian fund Brookfield (BN.TO), opens new tab plans to offer about 7 billion euros ($7.4 billion) for ...

Building upon a successful end-of-Phase 2 meeting, received FDA "Study May Proceed" letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agree ...

Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 ...

R&D expenses relating to fadraciclib were $0.9 million for the three months ended September 30 ... please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we ...

Top-line results from NCI/Alliance trial are expected to be presented ... please see the risk factors described in the company’s Annual Report on Form 10-K filed with the U.S. Securities and ...

Received tentative approval from the FDA for YUTREPIATM (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) ...

Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012† ...

PRMT5-MTA Data at ENA 2024 Additionally, Schrödinger will present new preclinical data on its PRMT5-MTA inhibitor program at a poster session during the meeting on October 25 from 9:00 a.m. - 3: ...

Absent any valid election to the contrary, shareholders (both holding in certificated and uncertificated form (CREST members)) and persons ... we may refer to Shell's "Net Carbon Intensity" (NCI), ...

Breast cancer patients have been given fresh hope after a new vaccine showed "promise" in treating an aggressive form of the ...